J Rhinol.  2023 Mar;30(1):15-22. 10.18787/jr.2022.00416.

Cost-Effectiveness Analysis of Uvulopalatopharyngoplasty Versus Positive Airway Pressure in Patient With Obstructive Sleep Apnea in South Korea

• Cho JH

• KMID: 2540853
• DOI: http://doi.org/10.18787/jr.2022.00416

Abstract

Background and Objectives
Although positive airway pressure (PAP) is known to be more effective than uvulopalatopharyngoplasty (UPPP) in the treatment of obstructive sleep apnea (OSA), PAP is a more expensive treatment in Korea. Therefore, it is necessary to compare the cost-effectiveness of these two treatments.
Methods
We assumed patients with moderate to severe OSA and divided them into three groups: those who used PAP (the PAP Treatment group), those who received UPPP (surgery group), and those who did not receive a diagnosis or treatment (No Treatment group). We compared their medical costs over 10 years. The incidence rate of common complications and accidents (coronary heart disease, heart failure, stroke, depression, diabetes, vehicle accident, and work-related accident) with or without treatment was adopted through a literature review. The average medical expenses for treating each complication and accident were also found by searching several databases.
Results
The incidence of all complications was higher in the control group than in the PAP Treatment group or the surgery group. However, since the absolute incidence rate was not high in all groups and medical expenses in Korea are low, the expected treatment cost was not high (KRW 108,209 per year for the PAP Treatment group, KRW 141,228 for the surgery group, and KRW 178,369 for the No Treatment group). In contrast, the costs of a polysomnography examination, PAP rental, and mask purchase were relatively high. Based on these results, the 10-year medical expenses for the PAP Treatment group were KRW 10,246,948, and those for the surgery were only KRW 925,095.
Conclusion
Although PAP treatment reduces the incidence of complications in OSA patients, it is not as cost-effective as UPPP in Korea, where medical costs are low.

Keyword

Obstructive sleep apnea; Cost-effectiveness analysis; Positive airway pressure; Uvulopalatopharyngoplasty

Reference

References

1. Korean Rhinologic Society. Snoring and sleep apnea. Seoul: Korean Rhinologic Society;2016.

2. Health Insurance Review & Assessment Service. [Health insurance medical care benefit costs]. Wonju: Health Insurance Review & Assessment Service;2022.

3. Healthcare Bigdata Hub. Medical statistics information [Internet]. Wonju: Health Insurance Review & Assessment Service; [cited 2020 Mar 20]. Available from: https://opendata.hira.or.kr/home.do.

4. Sher AE, Schechtman KB, Piccirillo JF. The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sleep. 1996; 19(2):156–77.

5. He M, Yin G, Zhan S, Xu J, Cao X, Li J, et al. Long-term efficacy of uvulopalatopharyngoplasty among adult patients with obstructive sleep apnea: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019; 161(3):401–11.

6. Kim Y, Shin S, Park J, Jung YJ, Kim J, Lee TJ, et al. Costing methods in healthcare. Seoul: National Evidence-based Healthcare Collaborating Agency;2013. p. 1–181.

7. Kim H, Kim JK, Cho JH. Cost-effectiveness analysis of positive airway pressure in patient with obstructive sleep apnea. J Rhinol. 2021; 28(2):94–101.

8. Cho JH, Suh JD, Han KD, Lee HM. Uvulopalatopharyngoplasty reduces the incidence of depression caused by obstructive sleep apnea. Laryngoscope. 2019; 129(4):1005–9.

9. Lee HM, Kim HY, Suh JD, Han KD, Kim JK, Lim YC, et al. Uvulopalatopharyngoplasty reduces the incidence of cardiovascular complications caused by obstructive sleep apnea: results from the national insurance service survey 2007-2014. Sleep Med. 2018; 45:11–6.

10. Streatfeild J, Hillman D, Adams R, Mitchell S, Pezzullo L. Cost-effectiveness of continuous positive airway pressure therapy for obstructive sleep apnea: health care system and societal perspectives. Sleep. 2019; 42(12):zsz181.

11. Bae JY. [Polysomnography prescription status]. Doctors Times [Internet]. 2019 Sep 19 [cited 2022 Mar 20]. Availabel from: http://www. doctorstimes.com/news/articleView.html?idxno=209022.

12. Ministry of Health and Welfare. Criteria and method of medical benefit for nursing expenses. Article 5-3 (positive pressure therapy device). Notice no. 2020-275 [Internet]. Sejong: Ministry of Health and Welfare;[cited 2020 Mar 20]. Available from: https://www.law.go.kr/LSW/admRulLsInfoP.do?admRulSeq=2100000207717#AJAX.

13. National Health Insurance Service. [Q&A related to the application of positive airway care costs] [Internet]. Wonju: National Health Insurance Service;2018. [cited 2020 Mar 20]. Available from: https://www.nhis.or.kr/static/html/wbma/c/wbmac0228_9.pdf.

14. Chang JH, Chung HJ, Chun S, Kim JH, Park SJ, Lee SY. Analysis of routine ENT preoperative assessment using Korean national health insurance database. Korean J Otorhinolaryngol-Head Neck Surg. 2022; 65(9):521–32.

15. Traffic Accident Analysis System. [Estimation and evaluation of road traffic accident costs (statistics of 2020)]. Wonju: KoROAD;2021.

16. Ministry of Employment and Labor. [2020 Industrial accident compensation insurance business annual report]. Sejong: Ministry of Employment and Labor;2021.

17. Guest JF, Panca M, Sladkevicius E, Taheri S, Stradling J. Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K. Diabetes Care. 2014; 37(5):1263–71.

18. Català R, Villoro R, Merino M, Sangenís S, Colomés L, Hernández Flix S, et al. Cost-effectiveness of continuous positive airway pressure treatment in moderate-severe obstructive sleep apnea syndrome. Arch Bronconeumol. 2016; 52(9):461–9.

19. Ayas NT, FitzGerald JM, Fleetham JA, White DP, Schulzer M, Ryan CF, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med. 2006; 166(9):977–84.

20. Tan MC, Ayas NT, Mulgrew A, Cortes L, FitzGerald JM, Fleetham JA, et al. Cost-effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnea-hypopnea in British Columbia. Can Respir J. 2008; 15(3):159–65.

21. Mansournia MA, Altman DG. Population attributable fraction. BMJ. 2018; 360:k757.

22. Hillman D, Mitchell S, Streatfeild J, Burns C, Bruck D, Pezzullo L. The economic cost of inadequate sleep. Sleep. 2018; 41(8):zsy083.